RXO · RXO
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $34.05
Note written ·
Price against the kill line
16.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $34.05, on record since 11 November 2026. The shares are up 21.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $34.05, above the 52-week high and the $30.25 announcement value, which would show the shares leading the S&P 500; a rival bid or a raised offer for RXO would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Industrials
Quarter to 30 September 2026, filed 29 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 1,871
- Revenue, change on a year (%)
- +31.7
- Gross margin (%)
- 17.8
- Operating margin (%)
- 0.9
- Free cash flow, four quarters ($M)
- −73.0
- Net cash, cash less debt ($M)
- −471
- Enterprise value to sales (×)
- 0.8
- Free-cash-flow yield (%)
- −1.6
All filed numbers
What RXO reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 1,871 | +31.7 | 17.8 | 0.9 |
| first filed | 1,774 | +25.0 | 17.0 | 0.1 |
| first filed | 1,425 | −0.6 | 17.8 | −2.0 |
| first filed | 1,469 | −11.9 | 18.1 | −2.9 |
| first filed | 1,421 | +36.6 | 20.0 | −0.5 |
| first filed | 1,419 | +52.6 | 21.2 | 0.0 |
| Pre-tax income ($M) | 6.0 |
| Net income ($M) four quarters: −88.0 | 3.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.0 |
| Operating cash flow ($M) | −15.0 |
| Capital spending ($M) | 58.0 |
| Free cash flow ($M) | −73.0 |
| Cash and short-term investments ($M) | 25.0 |
| Debt ($M) | 496 |
| Net cash, cash less debt ($M) | −471 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) +218.8% on a year | 51.0 |
| Receivables ($M) | 1,478 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 1,516 |
| Market value ($M) | 4,688 |
| Enterprise value, market value plus net debt ($M) | 5,159 |
| Enterprise value to sales (×) | 0.8 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.1 |
| Free-cash-flow yield (%) | −1.6 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 6.6% of shares outstanding sold short, 1.8 days of average trading to cover, −24.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $6.6M | $0 |
The thesis
RXO, Inc. trades as the target of C.H. Robinson's pending takeover, so its shares are more likely to lag the S&P 500 than lead it. The offer caps the upside, and the price follows C.H. Robinson's stock and deal risk more than RXO's own results. US antitrust review, C.H. Robinson's registration statement and the RXO shareholder vote settle the outcome, with closing targeted for the first half of 2027.
The terms are unchanged. Each RXO share gets $17.25 in cash plus 0.0856 C.H. Robinson shares. At the 5 October 2026 announcement that was worth $30.25, based on C.H. Robinson's 16-day volume-weighted average price of $151.88. Holders can elect $30.25 in cash or 0.1992 C.H. Robinson shares instead, subject to proration, per RXO's merger filings.
The shares already reflect a high chance that the deal closes. RXO closed at $28.14 on 11 November 2026. That is below the $30.25 announcement value and the $30 to $30.25 analyst targets, and the gap reflects time to closing, antitrust risk and C.H. Robinson's lower share price. The rating is Low because the fixed cash portion and the price ceiling leave little room for the shares to beat the index over three months, unless a rival bid appears or C.H. Robinson's stock rallies sharply.
Bullish and bearish views on RXO, Inc.
The bull case on RXO, Inc. (RXO), in brief: the regulatory process has started. The bear case: the stock portion has lost value.
Bull case
- The regulatory process has started. C.H. Robinson's 28 October 2026 earnings deck lists the Hart-Scott-Rodino (HSR) US antitrust filing and the Canada and Mexico filings as submitted. It keeps the first half of 2027 as the expected close.
- Financing is not a closing condition. RXO's 5 October 2026 Form 8-K states that the deal does not depend on C.H. Robinson obtaining financing. Merger filings describe up to $4.5 billion of committed bridge financing behind the cash portion.
- RXO's third quarter beat its guidance. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $51 million, against guidance of $35–45 million and $32 million a year earlier, per RXO's 29 October 2026 Form 8-K. Revenue was $1.871 billion, up from $1.421 billion.
- The acquirer expects large cost savings. C.H. Robinson's 28 October 2026 deck projects about $300 million of net annual cost savings from the deal and mid-teens earnings accretion in 2028. Its third-quarter revenue rose 29.5% to $5.36 billion.
- Large holders back the deal. MFN Partners, with 17.04% of RXO's shares, signed a voting agreement supporting the merger, per the 5 October 2026 Form 8-K. Orbis Investments, also a large holder, supports the deal, per coverage of the announcement.
Bear case
- The stock portion has lost value. C.H. Robinson fell 11.1% to close at $127.60 on 28 October 2026, per Simply Wall St, well below the $151.88 average behind the $30.25 figure. Susquehanna cut its C.H. Robinson target to $166 from $180 on 2 November 2026, per GuruFocus.
- The acquirer's cash generation weakened. C.H. Robinson's third-quarter cash from operations was $124.1 million, against $275.4 million a year earlier, per coverage of its 28 October 2026 report. Its deck says share buybacks are paused and targets net leverage of 1.75x–2.25x only by year-end 2028.
- The termination terms favor the buyer. RXO's 5 October 2026 Form 8-K describes a $175 million fee payable by RXO in specified circumstances. The outside date is 4 July 2027, with two three-month extensions if only regulatory conditions remain.
- RXO's margins are thinning. Gross margin fell to 14.6% from 16.5%, and truckload spot volume rose to 51% of the mix from 29%, per the 29 October 2026 Form 8-K. That leaves results more exposed to swings in spot freight rates before the vote.
- Analysts see no room above the offer. UBS raised its RXO target to $30.25 from $23 on 4 November 2026, and Susquehanna raised its target to $30 from $19 on 2 November 2026, both with neutral ratings, per Benzinga.
Price setup
RXO closed at $28.40 on 4 November 2026, $27.60 on 6 November 2026 and $28.14 on 11 November 2026, per adjusted daily closes. That close is 5.9% below the 52-week intraday high of $29.90 set on 21 July 2026. The 52-week closing low is $10.48, from 20 November 2025.
The shares rose 20.7% over three months, from $23.32 on 13 August 2026. That period includes the takeover announcement. As of 11 November 2026, the 50-day moving average is $24.77 and the 200-day moving average is $21.56. Both moving averages still reflect prices from before the deal, so they say little about where the shares trade now.
The price now trades in a narrow range below the offer value. Since 4 November 2026, closes have stayed between $27.60 and $28.40. Published analyst targets cluster at $30 to $30.25, all tied to the announcement value.
Catalysts ahead
- ~27 November 2026 (est.): End of the initial HSR antitrust waiting period, estimated from the 28 October 2026 deck listing the filing as submitted. Expiry with no second request would remove the main US regulatory hurdle; a second request would extend review and threaten the first-half-2027 timetable.
- ~30 November 2026 (est.): C.H. Robinson Form S-4 filing with the RXO proxy statement, guided for the fourth quarter of 2026. The filing sets out the deal background and regulatory status, and it must take effect before the RXO shareholder vote.
- ~15 February 2027 (est.): RXO fourth-quarter 2026 results. A sharp profit decline could raise questions about a material change in RXO's business before the vote; a strong quarter matters less while the offer caps the price.
- ~30 June 2027 (est.): Expected merger close (first half of 2027). With approvals, each RXO share converts into $17.25 cash plus 0.0856 C.H. Robinson shares, subject to election and proration.
What would change the view
A daily close above $34.05, above the 52-week high and the $30.25 announcement value, which would show the shares leading the S&P 500; a rival bid or a raised offer for RXO would also prove the call wrong.
What it trades with
RXO's closest link is C.H. Robinson. Each $1.00 move in C.H. Robinson's shares changes the deal value by $0.0856 per RXO share, while the $17.25 cash portion stays fixed. Elections are prorated, which keeps the total near 57% cash and 43% stock. BusinessQuant listed C.H. Robinson at $125.33 on 6 November 2026, below its $127.60 close of 28 October 2026.
The rest of the price reflects deal risk. Antitrust news can move RXO apart from freight stocks and from the S&P 500. This reading would be wrong if RXO repeatedly moved against C.H. Robinson on days without deal news.
The evidence, claim by claim (8)
- C.H. Robinson agreed to acquire RXO for $17.25 in cash plus 0.0856 C.H. Robinson shares per RXO share, an implied $30.25 based on a $151.88 16-day volume-weighted average price. RXO Form 8-K and third-quarter 2026 Form 10-Q · as of
- RXO holders may elect $17.25 cash plus 0.0856 C.H. Robinson shares, $30.25 in cash, or 0.1992 C.H. Robinson shares per RXO share, subject to proration. RXO Form 425 merger communication · as of
- The merger's outside date is 4 July 2027, with two three-month extensions; RXO may owe a $175 million termination fee; closing is not conditioned on financing. RXO Form 8-K on the merger agreement · as of
- C.H. Robinson's earnings deck lists the US antitrust (HSR) filing and the Canada and Mexico merger filings as submitted, with the Form S-4 to be filed in the fourth quarter of 2026. C.H. Robinson third-quarter 2026 earnings deck, Form 8-K · as of
- RXO third-quarter 2026 adjusted EBITDA was $51 million, above its $35-45 million guidance and up from $32 million a year earlier; revenue was $1.871 billion versus $1.421 billion. RXO Form 8-K, third-quarter 2026 results release · as of
- RXO gross margin fell to 14.6% from 16.5%, and truckload spot volume rose to 51% of the mix from 29% a year earlier. RXO Form 8-K, third-quarter 2026 results release · as of
- C.H. Robinson shares fell 11.1% to close at $127.60 after its third-quarter report. Simply Wall St · as of
- UBS raised its RXO target to $30.25 from $23 on 4 November 2026 and Susquehanna raised its target to $30 from $19 on 2 November 2026; both kept neutral ratings. Benzinga analyst reports · as of
Sources
- RXO, Inc. - Form 8-K - FY2026 · sec.gov ·
- C. H. ROBINSON WORLDWIDE, INC. - Form 8-K - FY2026 · sec.gov ·
- RXO, Inc. - Form 10-Q - FY2026 · sec.gov
- RXO (RXO) holders would choose cash, stock or both in the planned C.H. Robinson merger. · stocktitan.net
- An up-to-$4.5B bridge commitment supports C.H. Robinson's planned acquisition of RXO (RXO). · stocktitan.net
- C.H. Robinson Agrees to Buy RXO in $5.8 Billion Cash-and-Stock Deal · supplychain247.com
- CHRW Maintained by Susquehanna -- Price Target Lowered to $166 · gurufocus.com
- C. H. Robinson Worldwide CHRW · businessquant.com
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…